Previous 10 | Next 10 |
Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award PR Newswire Inmazeb is the first FDA-approved treatment for Zaire ebolavirus TARRYTOWN, N.Y. , Oct. 28, 2022 ...
Regeneron ( NASDAQ: REGN ) dropped ~2% pre-market Wednesday after Raymond James downgraded the pharma giant to Underperform from Market Perform, citing concerns on the future of its eyecare franchise led by anti-VEGF agent Eylea. Regeneron ( REGN ) surged in Septembe...
Summary Bronte Capital Amalthea Fund gained 6.68% for September and lost 0.32% across the quarter. Whilst quality has outperformed very low quality stocks over the quarter it was nowhere near what we would expect at this stage for a secularly weak market. Our short book has be...
Summary Today is a great time to invest for the long run, though the market may very likely experience more volatility before once again resuming its march higher. We expect meaningful market share gains from most if not all of our investments. Returns from here will be powere...
Summary Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point. Tekla Life Sciences invests in a collection of biotechnology, pharmaceutical, diagnostics, and other healthcare-related companies. ...
Regeneron Pharmaceuticals ( NASDAQ: REGN ) announced Friday that the FDA awarded pediatric exclusivity for its blockbuster eye therapy Eylea extending its U.S. market exclusivity by another six months through May 17, 2024. The decision was backed by data from two Phase 3 t...
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection PR Newswire TARRYTOWN, N.Y. , Oct. 21, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administr...
Summary HQH is able to generate strong and steady yield which is good enough to ignore the price loss suffered by this fund in a market that’s bearish overall. HQH is in a better position to hold up to its current price, and as it trades at a good discount to its NAV, chanc...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With all the vagaries in the market these days, investors may be better served considering undervalued biotech stocks to buy. At the most basic level, biotechnology firms aim to address critical vulnerabilities in the human...
Decibel Therapeutics ( NASDAQ: DBTX ), which is focused on hearing loss treatments, is up 25% in Tuesday morning trading after Eli Lilly ( NYSE: LLY ) said it would acquire fellow hearing therapy company Akouos ( NASDAQ: AKUS ) . One of Decibel's ( ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...